Development PipelineDisitamab vedotin

a novel, investigational antibody–drug conjugate directed to HER2

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

RC48 G001: HER2-expressing locally advanced or metastatic urothelial cancer (DV ± pembrolizumab)​

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of disitamab vedotin and ongoing clinical trials

Detailed information about disitamab vedotin clinical trials